King Pharmaceuticals Inactive 10-K2009 FY Annual report

Filed: 26 Feb 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: advisory, Albac, alter, altering, Anchorage, antagonize, antimicrobial, Appendix, Aurofac, autoinjector, await, BMD, bore, broadly, Chancery, Chlormax, Clean, clearer, concept, Connecticut, Conservation, contacted, Contemporaneously, Cook, crutchfield, Cycostat, Cygro, deadlocked, Deccox, derace, derecognizing, deterrent, devalue, docketed, Embeda, enterprise, euphoria, fed, fewer, Histostat, hydrochloride, hydrocholoride, intramuscularly, jurisdiction, kevin, Leon, likeability, mark, Montgomery, NGA, nontherapeutic, observable, oppose, opposed, orderly, path, pharmacokinetic, pollution, preacquisition, Purdue, QSPE, Rankin, reclassified, reclassify, reloadable, resubmission, resubmit, resubmitting, Richland, Robenz, Rofenaid, schaffer, similarly, sue, Superior, supervision, swap, tampered, transparency, unamortized, undertaken, unduly, wait, warning, Watson, Western

Removed: adjusting, advanced, affiliated, allosteric, announcement, aware, bargaining, Benevolent, Brotherhood, capability, charitable, collective, consistently, Conversely, convert, deployment, description, devoted, disciplined, disputed, disqualification, driven, duty, effectively, enhancer, facsimile, fiduciary, FIN, gaining, Green, Hale, IBMC, improperly, indemnified, interpretation, Ireland, loaned, Lupin, mature, measuring, Methodist, Milligan, Mississauga, mobilization, moving, neuropathic, nonprofit, occupied, Ontario, operative, ordered, Organon, owed, panel, Parkedale, partner, phased, planning, preexisting, profile, prudent, purported, redetermination, referred, refunded, RegistrationNo, Remoxytm, renew, repurchased, Rock, shortened, Southern, structure, surge, terrorist, treat, underpayment, unpredictability, upward, USA, utilized, variously, Warehousemen, wrote

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

King Pharmaceuticals similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this annual report onForm 10-K of King Pharmaceuticals, Inc. I, Brian A. Markison, Chief Executive Officer of King Pharmaceuticals, Inc., certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in this report fairly presents, in all material respects, the financial condition and results of operations of King Pharmaceuticals, Inc.

/s/ Brian A. Markison

Brian A. Markison

President and Chief Executive Officer

Date: February 25, 2010